Nuclear receptors as drug targets in obesity, dyslipidemia and atherosclerosis

被引：0
作者：
Hansen, Michael K. [1 ]
Connolly, Thomas M. [1 ]
机构：
[1] Wyeth Res Discovery Translat Med, Collegeville, PA 19426 USA
来源：
CURRENT OPINION IN INVESTIGATIONAL DRUGS | 2008年 / 9卷 / 03期
关键词：
atherosclerosis; cardiovascular disease; dyslipidemia; farnesoid X receptor; liver X receptor; obesity; peroxisome proliferator-activated receptor;
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
Nuclear hormone receptors, including peroxisome proliferator-activated receptors (PPARs), liver X receptors (LXRs), and the farnesoid X receptor (FXR), are transcription factors involved in the regulation of essential metabolic functions, including glucose and lipid metabolism, reverse cholesterol transport, and the regulation of bile acids. This review summarizes new developments in the use of PPAR, LXR and FXR agonists for the treatment of obesity and cardiovascular diseases, including dyslipidemia and atherosclerosis. Currently available drugs and future areas of research for new therapies are also discussed.
引用
收藏
页码：247 / 255
页数：9
相关论文
共 112 条
  • [1] PPARs and their metabolic modulation: new mechanisms for transcriptional regulation?
    Ahmed, W.
    Ziouzenkova, O.
    Brown, J.
    Devchand, P.
    Francis, S.
    Kadakia, M.
    Kanda, T.
    Orasanu, G.
    Sharlach, M.
    Zandbergen, F.
    Plutzky, J.
    [J]. JOURNAL OF INTERNAL MEDICINE, 2007, 262 (02) : 184 - 198
  • [2] Genetic variation in PPARG encoding peroxisome proliferator-activated receptor γ associated with carotid atherosclerosis
    Al-Shali, KZ
    House, AA
    Hanley, AJG
    Khan, HMR
    Harris, SB
    Zinman, B
    Mamakeesick, M
    Fenster, A
    Spence, JD
    Hegele, RA
    [J]. STROKE, 2004, 35 (09) : 2036 - 2040
  • [3] Hepatic cholesterol metabolism and resistance to dietary cholesterol in LXRβ-deficient mice
    Alberti, S
    Schuster, G
    Parini, P
    Feltkamp, D
    Diczfalusy, U
    Rudling, M
    Angelin, B
    Björkhem, I
    Pettersson, S
    Gustafsson, JÅ
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 2001, 107 (05) : 565 - 573
  • [4] Fenofibrate reduces progression to microalbuminuria over 3 years in a placebo-controlled study in type 2 diabetes: Results from the Diabetes Atherosclerosis Intervention Study (DAIS)
    Ansquer, JC
    Foucher, C
    Rattier, S
    Taskinen, MR
    Steiner, G
    [J]. AMERICAN JOURNAL OF KIDNEY DISEASES, 2005, 45 (03) : 485 - 493
  • [5] Fibrates: What have we learned in the past 40 years?
    Backes, James M.
    Gibson, Cheryl A.
    Ruisinger, Janelle E.
    Moriarty, Patrick M.
    [J]. PHARMACOTHERAPY, 2007, 27 (03): : 412 - 424
  • [6] PPARδ:: a dagger in the heart of the metabolic syndrome
    Barish, GD
    Narkar, VA
    Evans, RM
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 2006, 116 (03) : 590 - 597
  • [7] Bays Harold, 2007, Diab Vasc Dis Res, V4, P181
  • [8] Nuclear receptors in lipid metabolism: Targeting the heart of dyslipidemia
    Beaven, SW
    Tontonoz, P
    [J]. ANNUAL REVIEW OF MEDICINE, 2006, 57 : 313 - 329
  • [9] Bhatia V, 2006, CURR OPIN INVEST DR, V7, P891
  • [10] Expression and activation of the farnesoid X receptor in the vasculature
    Bishop-Bailey, D
    Walsh, DT
    Warner, TD
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2004, 101 (10) : 3668 - 3673
12345678910